Comorbidity evaluation tool shows usefulness for elderly nasopharyngeal carcinoma patients

  • Wen YF & al.
  • J Cancer
  • 01.01.2019

  • von Brian Richardson, PhD
  • Studien – kurz & knapp
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • The Adult Comorbidity Evaluation-27 (ACE-27) score is associated with cancer-specific survival (CSS) in patients aged ≥70 years with locoregionally advanced nasopharyngeal carcinoma (NPC).

Why this matters

  • Better prognostic tools can help guide patient management.

Key results

  • ACE-27 score ≥2 was associated with reduced CSS in multivariate analysis (HR, 2.359; P<.001 style="list-style-type:circle;">
  • ACE-27 score was also associated with OS (HR, 2.350; P<.001 pfs p and locoregional relapse-free survival>
  • Addition of chemotherapy to intensity-modulated radiotherapy (IMRT) was not associated with changes in 3-year CSS rates compared with IMRT alone in multivariate analysis (HR, 1.221; P=.419) or propensity score-matched analysis (64.3% vs 65.2%; P=.764).
  • In subgroup analysis, the addition of chemotherapy to IMRT was associated with a lower 3-year CSS rate compared with IMRT alone in patients with an ACE-27 score ≥2 (46.3% vs 63.5%; P=.041).
  • Study design

    • 206 patients aged ≥70 years with locoregionally advanced NPC who received IMRT with or without chemotherapy were analyzed for CSS and associations with ACE-27 score.
    • Funding: National Key R&D Program of China; National Natural Science Foundation of China; Sun Yat-Sen University, Guangzhou City; National Key Basic Research Program of China, Guangdong Province; others.

    Limitations

    • Retrospective study with short follow-up.